Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model

Virology

Volumn 430, Issue 1, 2012, Pages 10-19

  Bourgine, Maryline ^a,b   Dion, Sarah ^a,b   Godon, Ophélie ^a,b   Guillen, Gerardo ^c   Michel, Marie Louise ^a,b   Aguilar, Julio Cesar ^c  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Hepatitis B; Heterologous prime boost; Therapeutic vaccine; Transgenic mice

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

ANIMALIA; HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 84861822888     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.04.007     Document Type: Article

References (33)

1. Aguilar J.C., Lobaina Y., Muzio V., Garcia D., Penton E., Iglesias E., Pichardo D., Urquiza D., Rodriguez D., Silva D., Petrovsky N., Guillen G. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol. Cell Biol. 2004, 82(5):539-546.
2. Babinet C., Farza H., Morello D., Hadchouel M., Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985, 230(4730):1160-1163.
3. Betancourt A.A., Delgado C.A., Estevez Z.C., Martinez J.C., Rios G.V., Aureoles-Rosello S.R., Zaldivar R.A., Guzman M.A., Baile N.F., Reyes P.A., Ruano L.O., Fernandez A.C., Lobaina-Matos Y., Fernandez A.D., Madrazo A.I., Martinez M.I., Banos M.L., Alvarez N.P., Baldo M.D., Mestre R.E., Perez M.V., Martinez M.E., Escobar D.A., Guanche M.J., Caceres L.M., Betancourt R.S., Rando E.H., Nieto G.E., Gonzalez V.L., Rubido J.C. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J. Infect. Dis. 2007, 11(5):394-401.
4. Bocher W.O., Herzog-Hauff S., Schlaak J., Meyer zum Buschenfeld K.H., Lohr H.F. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999, 29(1):238-244.
5. Chisari F.V. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
6. Endmann A., Baden M., Weisermann E., Kapp K., Schroff M., Kleuss C., Wittig B., Juhls C. Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 2010, 28(21):3642-3649.
7. Farza H., Salmon A.M., Hadchouel M., Moreau J.L., Babinet C., Tiollais P., Pourcel C. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc. Natl. Acad. Sci. USA 1987, 84(5):1187-1191.
8. Ferrari C., Penna A., Bertoletti A., Valli A., Antoni A.D., Giuberti T., Cavalli A., Petit M.A., Fiaccadori F. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 1990, 145(10):3442-3449.
9. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284(5415):825-829.
10. Heermann K.H., Goldmann U., Schwartz W., Seyffarth T., Baumgarten H., Gerlich W.H. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 1984, 52(2):396-402.
11. Huang C.F., Lin S.S., Ho Y.C., Chen F.L., Yang C.C. The immune response induced by hepatitis B virus principal antigens. Cell Mol. Immunol. 2006, 3(2):97-106.
12. Jenna S., Sureau C. Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles. J. Virol. 1999, 73(4):3351-3358.
13. Kallenius G., Pawlowski A., Brandtzaeg P., Svenson S. Should a new tuberculosis vaccine be administered intranasally?. Tuberculosis (Edinb) 2007, 87(4):257-266.
14. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21(3):346-351.
15. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A., Williams R., Vergani D., Naoumov N.V., Ferrari C., Bertoletti A. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 2000, 191(8):1269-1280.
16. Mancini M., Hadchouel M., Tiollais P., Pourcel C., Michel M.L. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J. Med. Virol. 1993, 39(1):67-74.
17. Mancini-Bourgine M., Fontaine H., Scott-Algara D., Pol S., Brechot C., Michel M.L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004, 40(4):874-882.
18. Michel M.L., Davis H.L., Schleef M., Mancini M., Tiollais P., Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA 1995, 92(12):5307-5311.
19. Michel M.L., Deng Q., Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 2011, 54(6):1286-1296.
20. Milich D.R., McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986, 234(4782):1398-1401.
21. Milich D.R., McLachlan A., Thornton G.B., Hughes J.L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987, 329(6139):547-549.
22. Moriyama T., Guilhot S., Klopchin K., Moss B., Pinkert C.A., Palmiter R.D., Brinster R.L., Kanagawa O., Chisari F.V. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990, 248(4953):361-364.
23. Nayersina R., Fowler P., Guilhot S., Missale G., Cerny A., Schlicht H.J., Vitiello A., Chesnut R., Person J.L., Redeker A.G., Chisari F.V. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993, 150(10):4659-4671.
24. Pajot A., Michel M.L., Fazilleau N., Pancre V., Auriault C., Ojcius D.M., Lemonnier F.A., Lone Y.C. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 2004, 34(11):3060-3069.
25. Pajot A., Michel M.L., Mancini-Bourgine M., Ungeheuer M.N., Ojcius D.M., Deng Q., Lemonnier F.A., Lone Y.C. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes Infect. 2006, 8(12-13):2783-2790.
26. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, 2010.
27. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., Moss B., Sette A., Chisari F.V. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 1995, 181(3):1047-1058.
28. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393(6684):474-478.
29. Rohrlich P.S., Cardinaud S., Firat H., Lamari M., Briand P., Escriou N., Lemonnier F.A. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int. Immunol. 2003, 15(6):765-772.
30. Schirmbeck R., Dikopoulos N., Kwissa M., Leithauser F., Lamberth K., Buus S., Melber K., Reimann J. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur. J. Immunol. 2003, 33(12):3342-3352.
31. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3(6):1101-1108.
32. Sigal L.J., Crotty S., Andino R., Rock K.L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999, 398(6722):77-80.
33. Urbani S., Boni C., Amadei B., Fisicaro P., Cerioni S., Valli M.A., Missale G., Ferrari C. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 2005, 41(4):826-831.